What is Prenetics?
Founded in 2014, Prenetics has evolved into a Nasdaq-listed powerhouse that bridges the gap between complex genetic science and consumer-facing healthcare. The company operates at the intersection of biotechnology and digital health, providing a comprehensive suite of services that includes early colorectal cancer screening, COVID-19 diagnostic solutions, and at-home medical testing. By integrating mobile technology with rapid point-of-care diagnostics, Prenetics effectively decentralizes the traditional clinical experience.
The company's market position is defined by its ability to operate across diverse international regulatory environments, including India, South Africa, and the United Kingdom. This geographic diversification, combined with a focus on actionable health insights, allows Prenetics to maintain a competitive edge in the rapidly expanding personalized medicine market. Its platform-centric approach ensures that diagnostic data is not only collected but also utilized to drive long-term patient engagement and preventative health outcomes.
How much funding has Prenetics raised?
Prenetics has raised a total of $82.7M across 4 funding rounds:
Angel/Seed
$2.6M
Series A
$10M
Series B
$40M
Other Financing Round
$30M
Angel/Seed (2014): $2.7M with participation from 500.com, SXE Ventures, and Coent Venture Partners
Series A (2016): $10M led by Lippo Group, 500.com, COENT Venture, Venturra, Ping An, and Capital Union Investments
Series B (2017): $40M supported by Venturra, Ping An Ventures, and Beyond Ventures
Other Financing Round (2024): $30M featuring Insighta
Key Investors in Prenetics
Venturra
A Southeast Asia-based venture capital firm that invests in early-stage, high-growth technology-enabled companies with the ambition to redefine industries.
Ping An Ventures
A specialized financial services group originating from China, focusing on insurance, banking, and investment banking sectors.
Beyond Ventures
A United Kingdom-based firm operating within the telecommunications and technology investment space, supporting high-potential ventures.
What's next for Prenetics?
With the recent influx of $30M, Prenetics is well-positioned to accelerate its strategic roadmap, focusing on the expansion of its diagnostic infrastructure and the enhancement of its personalized care platforms. The company is expected to leverage this capital to deepen its penetration in existing markets while exploring new frontiers in point-of-care technology. As the healthcare industry shifts toward a more proactive, data-driven model, Prenetics is poised to capitalize on the increasing demand for at-home diagnostic solutions.
Future growth will likely be characterized by continued investment in R&D to refine its genetic testing capabilities and the potential for strategic partnerships that further integrate its services into the broader insurance and financial services ecosystems. By maintaining its focus on accessibility and technological innovation, Prenetics is set to remain a critical component of the global health-tech landscape, providing the necessary tools for individuals to take control of their health outcomes.
